Volume 4; Issue 3

Main
The Lancet Haematology
Volume 4; Issue 3

The Lancet Haematology

Volume 4; Issue 3

1

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Oliva, Esther N, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Salvi, Flavia, Sanpaolo, Grazia, Balleari, Enrico, Germing, Ulrich, Fenaux, Pierre, Stamatou

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 845 KB

english, 2017

2

Direct oral anticoagulants for superficial-vein thrombosis

Ageno, Walter, Dentali, Francesco

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 121 KB

english, 2017

3

Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial

Beyer-Westendorf, Jan, Schellong, Sebastian M, Gerlach, Horst, Rabe, Eberhard, Weitz, Jeffrey I, Jersemann, Katja, Sahin, Kurtulus, Bauersachs, Rupert

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 330 KB

english, 2017

4

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial

Ferreri, Andrés J M, Sassone, Marianna, Zaja, Francesco, Re, Alessandro, Spina, Michele, Rocco, Alice Di, Fabbri, Alberto, Stelitano, Caterina, Frezzato, Maurizio, Rusconi, Chiara, Zambello, Renato, C

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 1.05 MB

english, 2017

5

Diffuse large B-cell lymphoma: to maintain or not?

Coiffier, Bertrand

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 65 KB

english, 2017

6

Use of eltrombopag for treatment of myelodysplastic syndromes

Komrokji, Rami S

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 161 KB

english, 2017

7

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jones, Jeffrey A, Robak, Tadeusz, Brown, Jennifer R, Awan, Farrukh T, Badoux, Xavier, Coutre, Steven, Loscertales, Javier, Taylor, Kerry, Vandenberghe, Elisabeth, Wach, Malgorzata, Wagner-Johnston, Ni

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 1.12 MB

english, 2017

8

Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 147 KB

english, 2017

9

No pain, no gain: the forgotten patient-reported outcome?

The Lancet Haematology,

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 91 KB

english, 2017

10

Busulfan after HSCT in children and young adults – Authors' reply

Bartelink, Imke H, Lalmohamed, Arief, Long-Boyle, Janel R, Boelens, Jaap Jan

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 154 KB

english, 2017

11

Busulfan after HSCT in children and young adults

Paci, Angelo, Poinsignon, Vianney, Broutin, Sophie, Mir, Olivier, Vassal, Gilles

Journal:

The Lancet Haematology

Year:

2017

Language:

english

File:

PDF, 40 KB

english, 2017